GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » EPS without NRI

Scilex Holding Co (Scilex Holding Co) EPS without NRI : $-1.38 (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co EPS without NRI?

Scilex Holding Co's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.30. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.38.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -52.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Scilex Holding Co's EPS without NRI or its related term are showing as below:

SCLX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52   Med: -10.6   Max: 30.8
Current: -52

During the past 5 years, Scilex Holding Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 30.80% per year. The lowest was -52.00% per year. And the median was -10.60% per year.

SCLX's 3-Year EPS without NRI Growth Rate is ranked worse than
93.73% of 845 companies
in the Drug Manufacturers industry
Industry Median: 9.2 vs SCLX: -52.00

Scilex Holding Co's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.24. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.31.

Scilex Holding Co's EPS (Basic) for the three months ended in Mar. 2024 was $-0.24. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.31.


Scilex Holding Co EPS without NRI Historical Data

The historical data trend for Scilex Holding Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scilex Holding Co EPS without NRI Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
-1.17 -0.36 -0.59 -0.39 -1.28

Scilex Holding Co Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.16 -0.66 -0.25 -0.30

Competitive Comparison of Scilex Holding Co's EPS without NRI

For the Drug Manufacturers - General subindustry, Scilex Holding Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scilex Holding Co's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's PE Ratio without NRI falls into.



Scilex Holding Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scilex Holding Co  (NAS:SCLX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Scilex Holding Co EPS without NRI Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Scilex Holding Co (Scilex Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is engaged in the development and commercialization of non-opioid pain management products. The company's lead product ZTlido.
Executives
Sclx Stock Acquisition Jv Llc 10 percent owner 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Jay Chun director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Stephen Hoi Ma officer: Chief Financial Officer C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc. 10 percent owner 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
David Lemus director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Dorman Followwill director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Henry Ji director, officer: Executive Chairperson 5370 RUETTE DE MER, SAN DIEGO CA 92130
Jaisim Shah director, officer: See Remarks C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Elizabeth Czerepak officer: See Remarks 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Suneel G Kaji director 25/28 OLD BURLINGTON STREET, LONDON X0 W1S 3AN
Steve Myint director C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632

Scilex Holding Co (Scilex Holding Co) Headlines

From GuruFocus